Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806373 · ClinicalTrials.gov registry record · Phase 4
Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
A Phase 4 study, sponsored by Memorial Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT04806373 is a Phase 4 study that has completed, run by Memorial Healthcare System. The registered enrollment target is 27 participants.
The verdict
NCT04806373, a Phase 4 study, has completed, sponsored by Memorial Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.
Interventions
- DRUG Cathflo Activase
- DRUG Talc Slurry Pleurodesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2023-12-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04806373
The ClinicalTrials.gov registry entry for NCT04806373 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Healthcare System, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cathflo Activase is the first listed.
NCT04806373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04806373 about?
NCT04806373 is a clinical study titled "Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis". Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion.
What is the current status of trial NCT04806373?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2021-06-15. Estimated completion is 2023-12-14.
What interventions are being tested in trial NCT04806373?
The interventions under investigation include: Cathflo Activase (DRUG), Talc Slurry Pleurodesis (DRUG).
Who is sponsoring clinical trial NCT04806373?
This trial is sponsored by Memorial Healthcare System, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.